Exosomes, a new generation of theranostics
==========================================

Extracellular vesicles (EVs) are membrane-bound bionanoparticles secreted by all living cells into the extracellular space [@B1]. Based on their mode of biogenesis and size, EVs are classified as exomeres, exosomes, microvesicles, oncosomes or apoptotic bodies [@B2], [@B3]. From humble beginnings as "platelet-dust" half a century ago [@B4], EVs have emerged as key mediators for *in vivo* communication among cells, tissues and cross-kingdom molecules [@B2], [@B5]. Several decades of biochemical and cell biological investigations have culminated in recent works defining exosomes as 50 to 150 nm in size with surface tetraspanins (CD63, CD81, and CD9) as biomarkers and microvesicles as 100 to 1000 nm in size with annexin A1 as a distinct biomarker [@B6], [@B7]. In fact, exosomes circulating in various cell types have been found in the blood and other body fluids with cargos inherited from the cells of origin. These advances have laid the foundation for exosomes to be a novel source of biomarker discovery. Exosomes are known to carry a number of marker proteins, including heat shock proteins (HSPs), tumor-susceptibility gene 101 (Tsg101), the endosomal sorting complex required for transport (ESCRT-3) binding protein Alix, and major histocompatibility complex (MHC) class I and MHC class II complexes [@B8], [@B9]. Notably, integrins and other adhesion molecules on the surface of exosomes, such as intercellular adhesion molecule-1 (ICAM-1, also known as CD54) and lymphocyte function-associated antigen 1 (LFA-1) integrin, as well as the exosomal lipid content may facilitate exosome adhesion and fusion with the plasma membrane of recipient cells [@B10], [@B11]. In addition, the enrichment of specific transmembrane proteins, such as epidermal growth factor receptors (EGFRs) and epithelial cell adhesion molecule (EpCAM), in exosomes reflects their cellular origin [@B12], [@B13]. These proteins are associated with the normal physiology and pathogenesis of many diseases, leading to their utilization as valuable biomarkers [@B14]. The membranes of exosomes are highly enriched with lipid rafts, which render exosomes highly stable under various *in vivo* and *in vitro* conditions [@B15]. Given the unique lipid composition of their membrane, when compared with that of the cells from which they were derived, exosomes can effectively protect their cargos, such as proteins, mRNA, miRNA, long-noncoding RNA and small nuclear RNA. In addition to their pivotal roles in normal physiology and the pathogenesis of many diseases, exosomes are now poised to become promising next-generation diagnostic and therapeutic tools [@B16] (**Fig. [1](#F1){ref-type="fig"}**).

Indeed, exosomes carry information on not only their cells of origin, thus providing readily accessible diagnostic markers, but also the progression and prognosis of a particular disorder. For instance, cancer cell-derived exosomes can carry membrane proteins involved in cancer progression. A recent study on programmed death-ligand 1 (PD-L1) in exosomes from metastatic melanoma cells found that exosomal PD-L1 could inhibit CD8 T cells and facilitate tumor growth [@B17]. Another recent study demonstrated that integrins such as α6, αv and β1, found on cancer cell-derived exosomes could be used to distinguish between different types of cancer, such as breast, kidney, colon and ovarian cancers, and to predict tumor stage, as higher levels of these proteins on exosomes were secreted from the more aggressive progenitor cancer cells [@B18]. Moreover, miRNAs extracted from exosomes can be used as signatures for disease detection and as indicators of the tissue of origin not only in cancer [@B19] but also in other diseases such as neurodegenerative diseases [@B20], obesity [@B21], diabetes [@B22], lupus nephritis [@B23], cardiovascular diseases [@B24], and lung diseases [@B25]. It has been shown that at least some exosomes are able to cross the blood-brain barrier. Thus, the content and number of exosomes in the cerebrospinal fluid and plasma may provide valuable information on the pathogenesis and progression of neurodegenerative diseases [@B26]. In a recent study, plasma exosomes from subjects with HIV-associated neurological disorders and from healthy subjects were isolated using antibodies against the neuronal cell adhesion molecule L1 (L1CAM). The concentration of L1CAM^+^ neuronal exosomes was found to be lower in the neurocognitively impaired participants than that in the subjects without neurological impairment. In addition, increased levels of the neuronal markers neurofilament light (NfL) and synaptophysin were found in the neuron-derived exosomes in plasma from HIV-infected individuals [@B27]. β-amyloid (Aβ) plaques have been regarded as among the earliest hallmarks of the disease, and exosomal β-amyloid in the bloodstream has been utilized for the detection of Alzheimer\'s disease [@B28]. In addition, CD63/CD66b and CD63/MUC-1 double-positive exosomes in colonic luminal fluid aspirates from patients with inflammatory bowel disease were found to be of neutrophil and epithelial cell origin, respectively, and thus have been utilized as potential fecal biomarkers for mucosal bowel inflammation [@B29]. Interestingly, this dual positive exosome-based approach has also been applied in the development of novel methods for assessing placenta health via the analysis of circulating syncytiotrophoblast exosomes released from the placenta surface that directly entered maternal circulation [@B30]. Exosomes in the circulation that were positive for both a placenta-specific marker (PLAP) and an exosome marker, CD63, were found to gradually increase after 6 weeks gestation, indicating that the release of syncytiotrophoblast exosomes into maternal circulation occurs before the onset of blood flow into the intervillous space, which occurs at approximately 10 weeks gestation in a normal pregnancy [@B30]-[@B32]. Furthermore, exosomes harboring proteins involved in innate immunity in saliva and tears were also explored as potential biomarkers of primary Sjögren\'s syndrome [@B33], demonstrating the versatile use of exosomes in biofluids as biomarkers for staging and monitoring diseases.

The biological features of exosomes endow these vesicles with the ability to efficaciously deliver therapeutic molecules. The "homing effect" of exosomes indicates that exosomal therapeutics delivered are likely to induce more pronounced anticancer effects in cancer cells from which the exosomes are derived [@B34]. There is also evidence suggesting that mesenchymal stromal cell (MSC)-derived exosomes constitute a promising new modality for the treatment of stroke and traumatic brain injury. In this context, exosomes loaded with selected miRNAs can alter the biological functions of recipient cells [@B35]. Some clinical trials involving exosomes were recently registered, mostly in the contexts of stroke, diabetes, cutaneous wounds and cancer [@B35]. Undoubtedly, we will witness an increasing number of exosome-based therapies in the next few years once the biological functions, molecular mechanism(s) and the safety of exosomes, as well as their manufacturing and associated quality control procedures, are clarified and developed thoroughly.

Exosome-based liquid biopsy in precision oncology
=================================================

The survival and quality of life of patients with cancer can be significantly improved when the disease is diagnosed at an early stage. Thus, the early detection of cancer is pivotal for improving treatment outcomes and reducing the cancer burden. The methodologies used for early cancer detection should be sensitive, accurate, minimally invasive and able to be repeatedly performed on demand. To mitigate the limitations of traditional tissue biopsy, a liquid biopsy of biological fluids, such as blood or urine, has been utilized to detect cancer biomarkers with minimal invasiveness, making this technique suitable for obtaining multiple samples over time [@B36]-[@B38]. The successful clinical translation of liquid biopsies is exemplified by CellSearch^®^, a diagnostic test for cancer metastasis that detects circulating cancer cells in the blood, which was approved by U.S. Food and Drug Administration (FDA) in 2004. Liquid biopsy is also indispensable for monitoring therapeutic effectiveness in cancer patients undergoing treatment, as well as for providing real-time feedback and guidance on adjustments to optimize treatment regimens. The presence of EVs released by cancer cells in bodily fluids makes them accessible for simple and repeated sampling. Moreover, in some cases, cancer cells release more exosomes into plasma than do healthy cells, and a number of cancer-related biomarkers have been shown to be overexpressed in these cancer-derived exosomes [@B39], [@B40]. Exosome-associated membrane proteins are valuable for the isolation of exosomes and the characterization of their biological functions in cancer progression [@B37], [@B41]. The importance of developing potentially novel exosome-based cancer biomarkers has been extensively exploited. The amounts of specific proteins in exosomes, such as glypican 1 [@B42], [@B43], may constitute biochemical signatures for determining the stage of cancer. Indeed, elevated glypican-1 in circulating exosomes can be used for the early diagnosis of pancreatic cancer as the amount of exosomal glypican-1 correlates with tumor burden [@B42], [@B43]. In addition, the TYRP2 levels in exosomes were found to be significantly increased in the plasma of patients with stage III melanoma who eventually developed metastases [@B44]. Moreover, L1CAM, CD24 and extracellular matrix metalloproteinase inducers were shown to be increased in exosomes released from ovarian cancer cells in both malignant ascites and serum [@B45].

One interesting target protein for liquid biopsy development is EpCAM [@B46]. Elevated EpCAM levels are associated with increased cell proliferation, tumor development and progression, as well as with reduced overall survival of cancer patients [@B47]. As an epithelial marker, EpCAM is expressed at low levels in all epithelial cells. The blood of healthy subjects contains very few EpCAM-positive exosomes or EVs [@B48]-[@B50]. However, when normal epithelial cells transform into carcinoma cells, significantly more EpCAM-positive EVs are detected in both the general circulation and in other body fluids, such as pleural effusions [@B51] in patients with carcinomas [@B52]. Hence, circulating EpCAM-positive exosomes could be a minimally invasive diagnostic marker for the early detection of cancers of epithelial origin or carcinomas. Indeed, EpCAM-positive exosomes were harvested from the serum and/or the plasma of lung, ovarian and colorectal cancer patients using an anti-EpCAM antibody to establish novel cancer diagnostic methods [@B53]-[@B55]. While EpCAM-positive exosomes can be detected in both patients with benign ovarian disease and ovarian cancer, the exosomal miRNA profiles were remarkably distinct in cancer patients and patients with benign disease [@B53]. Interestingly, the miRNAs found in the exosomes from ovarian cancer patients were abundant and similar among patients, but they were not be detected in healthy subjects [@B53]. Similar results were found regarding the profiles of lung cancer patients and normal controls [@B54] and of colorectal cancer patients and healthy individuals [@B55]. Of note, miRNAs encapsulated by exosomes are remarkably stable in circulation because exosomes can protect miRNA against RNase-mediated degradation [@B55]. miRNA profiling has emerged as a robust and promising strategy for exosome-based diagnostics, as PCR-based miRNA profiling requires a much lower concentration of exosome than is required for protein-based exosome analysis [@B55]. Indeed, several research groups demonstrated that the association of miRNAs with circulating cancer- derived exosomes could be used as a signature for cancer diagnosis. For example, analyses of exosomal miRNAs revealed a differential expression pattern in patients with prostate cancer compared to controls. Specifically, in the prostate cancer samples, the levels of miR-100-5p and miR-21-5p were found to be valuable for evaluating prostate cancer progression and metastasis [@B56]. Furthermore, tumor-derived exosomal miRNAs, including the adenocarcinoma- specific miR-181-5p, miR-30a-3p, miR-30e-3p and miR-361-5p and the squamous cell carcinoma-specific miR-10b-5p, miR-15b-5p and miR-320b, have been shown to be potential biomarkers useful for distinguishing adenocarcinoma from squamous cell carcinoma in the early diagnosis of non-small cell lung cancer [@B57]. Most recently, a research group from Spain analyzed exosomal miRNA levels in serum samples from 53 women with breast cancer who had been initially diagnosed with localized breast cancer and who were receiving neoadjuvant chemotherapy, before and during the therapy, and compared the levels to those in eight healthy controls [@B58]. Exosomal miRNA-21 and miRNA-21-105 were found to be increased in the metastatic patients compared to the levels in the non-metastatic patients and the healthy donors before receiving neoadjuvant therapy. Importantly, the levels of miRNA-21 were found to be directly correlated with the tumor size during neoadjuvant therapy [@B58]. These intensive studies have culminated in a milestone in exosome-based cancer diagnostics: the FDA approval of the ExoDx^TM^ Prostate IntelliScore (EPI) test in June 2019. ExoDx^TM^, which is an exosomal RNA-based clinical liquid biopsy test based on a simple urine sample that provides a more precise diagnosis of prostate cancer [@B59]-[@B61].

In the past few years, several techniques have been established for the detection of a variety of proteins in exosomes and tumor-associated markers through liquid biopsy. ExoTEST is an enzyme-linked immunosorbent assay (ELISA)-based technique that captures and quantifies exosomes in plasma and other biological fluids by detecting CD63 and Rab5b proteins on exosomes and caveolin-1, a tumor-associated marker [@B62]. In a clinical study of ExoTEST, high levels of exosomes expressing CD63 and caveolin-1 were detected in the plasma of melanoma patients compared with that in the plasma of healthy controls [@B39]. Although exosomes released from cancer cells are thought to promote tumor growth and metastasis, their low abundance in the circulation in the early stages of cancer development constitutes a formidable challenge to the use of liquid biopsy. Nevertheless, employing multiple exosomal biomarkers, Yoshioka and colleagues employed multiple exosomal biomarkers to develop an antibody-based ExoScreen technique (**Fig. [2](#F2){ref-type="fig"}**) that can be used to monitor CD147-CD9 double-positive exosomes secreted from colorectal cancer cells in only 5 μL of patient serum [@B63]. Interestingly, this method does not require a prior purification step. Thus, ExoScreen is a highly sensitive and rapid liquid biopsy technique for the detection of disease-specific exosomes in circulation.

The inherent limitations of conventional exosome detection methods include the prolonged time, requirement for large amounts of exosomes and extensive post-labeling processes [@B64]. To address these issues, high-throughput approaches have been developed that use nanoplasmonic sensors for label-free detection, molecular profiling and multiplexed phenotyping of exosomal proteins [@B13], [@B65]. Label-free detection is a portable process that enables point-of-care analyses. For example, a nanoplasmonic exosome (nPLEX) assay was developed based on transmission surface plasmon resonance (SPR) and arrays of periodic nanoholes functionalized with antibodies to identify exosomal CD24 and EpCAM expression in ascites fluid from ovarian cancer patients [@B13]. In addition, a high-throughput-based molecular profiling technique for use with exosomes was established in the format of an exosome array, in which exosomes were first immobilized using antibodies against CD9/CD81/CD63 imprinted on coated glass slides. Subsequently, a panel of antibodies against 21 different cell surface antigens and cancer antigens was added. This method has been successfully applied for exosome profiling using 1-10 µL of plasma from healthy controls and patients with non-small cell lung carcinoma [@B65], [@B66]. Most recently, Zhang et al. enhanced the efficiency and speed of exosome capture using an ultrasensitive biosensor based on a self-assembled 3D herringbone nanoporous structure; the greater surface area of this sensor increased the number of exosomes that could contact the antibody-coated sensing surface [@B67]. This microfluidic chip was used for the rapid detection of exosomes expressing CD24, EpCAM and folate receptor α (FRα) in only 2 μL of plasma from ovarian cancer patients and healthy controls. This experiment revealed that FRα is a potential biomarker for the early detection and monitoring of ovarian cancer. In addition, the negative charge of exosomes was leveraged to promote electrostatic interactions with nickel at pH values above 5 under physiological conditions. Based on this principle, a simple yet robust strategy for the rapid purification of EVs was developed by combining nickel-based isolates with an amplified luminescent proximity homogeneous assay or droplet digital PCR. This strategy further evolved into an EV-based liquid biopsy used to probe tumor heterogeneity [@B68]. This method was applied to detect picomolar concentrations of exosomal prostate-specific membrane antigen (PSMA) in the plasma of prostate cancer patients. Impressively, the somatic BRAF and KRAS mutations in exosomes circulating in the plasma of metastatic colorectal cancer patients detected by this technique matched the tissue diagnostics with 100% concordance [@B68]. Another new exosomal profiling platform developed by Zhang and coworkers is the ExoProfile chip. This device was constructed of 3D porous serpentine nanostructures via patterned colloidal self-assembly to increase the number of reaction sites and improve the exosome biosensing efficiency. Hence, this device detects a panel of surface protein markers on exosomes, including EGFR, human epidermal growth factor receptor 2 (HER2), CA125, FRα, CD24, EpCAM, CD9 and CD63, with high sensitivity in a multiplexed manner [@B69]. This platform was applied to detect circulating EVs in only 10 μL of plasma from ovarian cancer patients in 3 hours, and the results demonstrated improved accuracy in differentiating early stage from late stage cancer [@B69]. For early cancer detection, Ramshani and colleagues developed a novel platform for the quantification of both free-floating miRNAs and EV-bound miRNAs in plasma, in which a surface acoustic wave lyses exosomes on a microfluidic chip integrated with another concentration-sensing chip that uses an electrokinetic membrane sensor to measure non-equilibrium ionic currents [@B70]. This microfluidic chip is a convenient tool for clinical analysis because it requires no exosome extraction, RNA purification, reverse transcription, or amplification and instead requires only a small volume of plasma (only 20 μL of plasma is needed for exosomal miRNA analysis) and can be performed in approximately 30 minutes with 1 pM sensitivity [@B70].

While blood is commonly obtained in liquid biopsy, clinicians may request urinary samples for certain types of cancer, such as bladder cancer [@B71] and prostate cancer [@B72]. Urinary exosomes have been shown to be promising biomarkers of renal-associated pathologies [@B73]. Increased α1-integrin and β1-integrin levels were found in urinary exosomes from metastatic prostate cancer patients compared to those from nonmetastatic patients [@B74]. In addition to its use in combination with tetraspanins (CD63, CD81 and CD9) as a general exosome marker, EpCAM is a specific urine exosomal marker of carcinoma cells that can be captured by antibody-coated magnetic microbeads [@B75]. Campos-Silva and coworkers demonstrated that only 500 μL of urine is required to isolate sufficient exosomes for detecting EpCAM expression by flow cytometry [@B75]. This study described a sensitive and reproducible method for the effective immunocapture of exosomes for future clinical applications. Finally, to address the challenge of the low abundance of urinary miRNAs, Wang and colleagues optimized a number of parameters for droplet digital PCR to achieve much higher sensitivity, reproducibility and accuracy than real-time quantitative PCR [@B76]. The exosome-based liquid biopsy techniques presented in this section are summarized in **Table [1](#T1){ref-type="table"}.**

Superiority of aptamers as targeting ligands
============================================

Aptamers, also known as chemical antibodies, are single-stranded DNA or RNA that fold into 3D structures and specifically bind to their targets with high affinity and specificity [@B80]. Aptamers are generated via a PCR-based *in vitro* selection strategy known as systematic evolution of ligands by exponential enrichment (SELEX) [@B81], [@B82] (**Fig. [3](#F3){ref-type="fig"}).** Owing to their advantages over conventional antibodies in terms of low immunogenicity and batch-to-batch variation, high specificity and sensitivity, as well as deeper tumor penetration [@B83], [@B84], aptamers have become an invaluable class of affinity ligands in biomedical research, diagnostics [@B85] and therapeutics [@B86]. For example, a DNA aptamer was developed by Wang and colleagues with superb targeting properties and distinctive functional versatility for early disease detection, imaging, and targeted delivery of therapeutic agents [@B87]. Liu et al. developed a cell-specific DNA aptamer-based fluorescence probe for the molecular subtyping of breast cancer [@B88]. This aptamer probe can distinguish, within 30 minutes, not only between different breast cancer cells but also between breast cancer cells and normal mammary epithelial cells, and between different tumors in mouse xenograft models of human breast cancer [@B88]. Such a robust aptamer has great potential to be further developed into a rapid and sensitive tool for guiding personalized therapy and determining prognosis [@B89], [@B90].

Aptamers are emerging as a new class of ligands for tracking tumors at the cellular, subcellular and molecular levels. Aptamers used in super-resolution microscopy offer many advantages over conventional antibody-based immunostaining methods, particularly in cases in which the affinity ligands themselves are larger than the protein of interest. Specifically, aptamer-based probes have improved detection sensitivity due to minimized steric hindrance, increased ligand density and high penetration into cells/tissues [@B91]. Indeed, studies from independent laboratories confirmed that the use of aptamers as detection ligands resulted in superior resolutions well below the light diffraction limit compared to the use of antibodies as probes [@B91]-[@B93]. Moreover, to achieve better resolution of aptamer-based probes, Spiegelmer technology has been used to select stable aptamer-based probes that achieve the best imaging quality. In this strategy, endonuclease-sensitive RNA aptamers (D-form) are replaced with endonuclease-resistant RNA aptamers (L-form) or mirror-image aptamers [@B91], [@B94].

The *in vivo* targeting of aptamers to tumor cells can be visualized by labeling with a suitable fluorescent agent or radionuclide. ^18^F-radiolabeled HER2-targeted DNA aptamers were developed and demonstrated high tumor uptake. Therefore, such aptamers hold promise as specific HER2-positive tumor imaging agents in positron emission tomography (PET) [@B95], [@B96]. In addition, FAM and Cy5 were used to label the R13 aptamer to investigate the mechanism of aptamer internalization and the ability to target ovarian cancer cells [@B97]. A bright, orange fluorescent turn-on probe (TMR-DN) bound to a rainbow aptamer, SRB-2, was used to improve the signal-to-background ratio in fluorescence imaging, providing low background fluorescence and enabling no-wash live-cell RNA imaging [@B98]. This novel aptamer-based system was used to image the distinct subcellular localization patterns of ribosomal RNA and mRNA in bacteria and mammalian cells [@B98]. A recent study showed that Cy5-labeled M17, a DNA aptamer that specifically recognizes MMP14, is a promising molecular probe for imaging numerous types of MMP14-positive cancer cells [@B99]. Moreover, the past 10 years have witnessed the development of quantum dot (QD)-labeled aptamers and their extensive applications in cancer theranostics [@B100], [@B101]. For example, a versatile, sensitive and selective sandwich assay involving a DNA aptamer and QDs as signal amplifiers was established for cancer detection [@B102]. Additionally, EGFR aptamer-conjugated lipid nanoparticles containing QDs and siRNAs were used to achieve remarkable EGFR-dependent siRNA delivery and fluorescence imaging [@B103].

Simple yet powerful aptamer sensors can be developed on a DNA module platform composed of an aptamer, a joint module for sensing a conformational change in the aptamer, a terminal stem, and a DNAzyme to report target detection in a concentration-dependent manner. Using such a strategy, Tomita and co-workers customized a microarray containing more than 10,000 sequences designed by *in silico* secondary structure predictions for array-based screening [@B104]. Aptamer-based biosensors have demonstrated practical application in point-of-care drug monitoring systems, whereby the circulating drug concentration can be detected in human serum [@B105]. For the design of such a point-of-care device, the biointerface of the sensor may consist of a binary self-assembled monolayer of a specific thiolated aptamer and 6-mercapto-1-hexanol (MCH, a surface blocking agent and aptamer spacer) at an optimized ratio based on electrochemical impedance spectroscopy measurements, which are used to enhance the sensitivity towards specific targets [@B106]. Memristive nanowires, assembled based on the regeneration properties of DNA aptamers on their surface, have also emerged as potential real-time monitoring tools for ultrasensitive, highly specific and selective drug biosensors. Such systems have been used for the successful detection of tenofovir in human serum [@B107]. Electrochemical aptamer-based sensors constitute another type of promising biosensor for the rapid, specific recognition and quantification of drugs such as insulin. In this device, a redox label-modified guanine-rich aptamer that folds into a G-quadruplex serves as as a probe to detect insulin, enabling researchers to discriminate insulin, glucagon and somatostatin in a Krebs-Ringer bicarbonate buffer [@B108]. Another sandwich-type electrochemical aptamer-based biosensor, known as an aptasensor, was designed with a combination of tetrahedral DNA aptamers and a flower-like nanozyme/horseradish peroxidase (HRP) combination and used for the detection of the breast cancer cell biomarker HER2 [@B109]. Specifically, in the assembly of this biosensor, the aptamer specifically binds to HER2 and the complex is immobilized on the gold electrode surface, where the Mn~3~O~4~- Pd\@Pt nanozymes are linked by another aptamer and natural enzyme HRP, collectively referred to as nanoprobe 1, to amplify the biosensor signal. To further amplify the signal, nanoprobe 1 is subsequently converted into dendritic DNA nanostructures via links with nanoprobe 2, a structure based on Pd\@Pt/HRP/cDNA [@B109].

Since the development of aptamer technology nearly 30 years ago, pegaptanib, an RNA aptamer against vascular endothelial growth factor (VEGF), is the only aptamer that has been approved by the FDA for the treatment of macular degeneration [@B110]. Nevertheless, a number of aptamers are undergoing preclinical and clinical development, including aptamers to thrombin, nucleolin and prostate-specific membrane antigen [@B111]. Three strategies have been commonly used for the therapeutic application of aptamers, namely, (i) aptamers as antagonists, (ii) aptamers as agonists, and (iii) aptamers as delivery agents [@B112]. All the aptamers in current clinical trials have been classified as category (i) aptamers, and the design of most must be improved to meet the expectations for therapeutic efficacy, such as the generation of a hybrid complex with an antibody [@B113], conjugation with cholesterol [@B114] or nanoparticles [@B115], or formulation as a multimer [@B116]. On the other hand, a few aptamers have been developed as agonists, and they include RNA aptamers against HER3/ERBB3, OX40 (CD134), 4-1BB (CD137), CD40 and CD28 and DNA aptamers targeting human VEGFR-2 and insulin receptor [@B112]. As targeting ligands in drug delivery systems, aptamers function to guide the systems to the desired cells/tissues to maximize treatment efficacy and minimize systemic toxicity [@B117]. By neutralizing histones with chemically stabilized anionic 2′ fluoro-modified RNA aptamers with high binding affinity, Giangrande\'s group demonstrated the efficacy of histone-specific aptamers in the treatment of multiple clinical conditions associated with multiple organ dysfunction syndrome [@B117]. One new tool generated by aptamer-based techniques for nanomedicine precision therapy is a DNA nanorobot. Ma et al. generated a new intelligent DNA nanorobot based on an anti-HER2 aptamer anchored to a tetrahedral nucleic acid framework for the selective lysosomal degradation of HER2 protein in breast cancer cells [@B118].

Although aptamers are promising ligands for targeted theranostics, one potential barrier for their translation into the clinic is the possible loss of targeting capacity under *in vivo* conditions. After performing studies to mitigate this concern, Tan\'s group recently reported the causes of this loss of targeting [@B119]. By determining variations in the surface chemistry and biological behavior of nanoparticles in serum, Tan\'s group identified several factors that contribute to the loss of efficacy of aptamer-guided nanocarriers. The rapid clearance of nanoparticles due to the immune response to the nanoparticle surface, aggregation of small nanoparticles, protein corona blocking, and enzymatic cleavage of the aptamer [@B119] are among the key mechanisms underlying the loss of aptamer-based targeting efficacy *in vivo*. Future smart design and engineering are expected to provide effective solutions to this problem.

Aptamer-guided exosome diagnostics and therapeutics
===================================================

The application of aptamer technology in both basic science research and the clinical translation of exosomes is poised to lead to the development of the next generation of diagnostics and therapeutics.

Aptamer-guided exosome diagnostics
----------------------------------

To exploit molecular markers on the surface of exosomes for improving exosome enrichment efficiency and facilitating exosome isolation, aptamers can be selected to specifically bind to the markers and thus capture the exosomes. The engineering of aptamer-guided exosome diagnostic tools is outlined in the following sections.

### Simple use of peptide/RNA/DNA aptamers to capture exosomes

By selecting an aptamer against an overexpressed protein on exosomes, an aptamer-guided exosome-capturing nanoplatform system can be developed as a diagnostic tool. Garrido and colleagues developed an aptamer against the A8 peptide that could bind to the extracellular domain of HSP70, which is overexpressed in many cancers [@B120]. This aptamer was utilized to capture HSP70-positive exosomes in urine samples from patients with breast, lung, or ovarian cancer [@B121]. This study demonstrates a key advantage of quantifying cancer-derived exosomes over determining the number of circulating tumor cells: there are more exosomes than cancer cells in systemic circulation. Moreover, exosomes can be quantified in both blood and urine. Murakami et al. selected two RNA aptamers of 55 and 30 nucleotides (nt) after several rounds of SELEX [@B122]. Both the 55- and 30-nt aptamers had strong affinity for exosomes, as analyzed by SPR, whereas circular dichroism spectroscopy revealed that the two aptamers could form a G-quadruplex structure in their loop regions that was stabilized by potassium ions [@B122]. In a separate work, Sun\'s group developed λ-DNA- and DNA aptamer-mediated approaches for the simultaneous size-selective separation and surface protein analysis of exosomes [@B123]. Impressively, a machine learning algorithm applied to exosomal size and marker signatures was able to distinguish various breast cell lines and stage II breast cancer patients with varied HER2 expression patterns [@B123].

### Aptasensor

Given their advantages of high sensitivity, rapid response, portability, and low sample volume requirement, aptasensors have become an important diagnostic tool for detecting cancer-derived exosomes [@B124] (**Fig. [4](#F4){ref-type="fig"}**).

Wang et al. presented a nanotetrahedron (NTH)-assisted electrochemical aptasensor as a sensitive and rapid tool for the direct capture and detection of exosomes secreted by hepatocellular carcinoma cells [@B125]. In this study, an aptamer containing one expanded nucleotide was generated against liver cancer cells, and it exhibited selectivity for exosomes secreted from HepG2 cells. The NTH-assisted aptasensors had improved specificity and capture efficiency. This study provides a strategy for overcoming the limitations of aptasensors that impede exosome detection, including the likelihood that immobilized aptamers on electrodes undergo self-assembled monolayer aggregation or entanglement and the inability to control the spatial orientation of single-stranded aptamers [@B125]. Another technical challenge relates to the efficient detection of cancer-derived exosomes among a background of exosomes secreted by non-cancerous cells in order to evaluate the diagnostic results or to gain a comprehensive understanding of the tumor migration and/or invasion mechanism. To overcome these challenges, Huang et al. developed a label‐free electrochemical aptasensor containing an anti‐CD63 antibody-modified gold electrode and an aptamer against mucin. The mucin aptamer was linked to a primer sequence complementary to a G‐quadruplex circular template and was used to detect gastric cancer exosomes [@B126]. The high sensitivity of this method was based on the effects of the hemin/G-quadruplex DNAzyme on H~2~O~2~ reduction to influence the production of electrochemical signals as well as a signal amplification step. This is achieved through rolling circle amplification, a reaction that generates high molecular weight products to accomplish signal amplification [@B126]. Such an electrochemical aptasensor has a detection limit of \~ 100 cancer biomarker-positive exosomes per milliliter.

### Other lab-on-a-chip-based diagnostic tools

Most aptamer-guided exosome diagnostic tools are based on the principle of selective binding between aptamers and exosome/disease markers. Inorganic materials and polymers are common components used in conjunction with aptamers to form integrated platforms for lab-on-a-chip exosomal diagnostic devices. Zhang and colleagues developed the ExoAPP assay, an aptamer nanoprobe-based exosome profiling system that can be used to phenotype exosome surface proteins and quantify cancer-derived exosomes [@B127]. This tool consists of a graphene oxide interfacing with aptamers against exosome markers. The profiling of exosome markers is achieved by the integration of enzyme-assisted exosome recycling. This assay can detect exosomes at the limit of 1.6 × 10^5^ particles/ mL. The ability of ExoAPP to identify surface PSMA on target exosomes in blood samples from prostate cancer patients is indicative of its future application in clinical diagnostics [@B127]. Furthermore, to enrich EpCAM-positive cancer-derived exosomes for clinical detection, Yoshida et al. developed an EpCAM‐affinity coating agent (EpiVeta) to be used on the surface of inorganic materials in diagnostic devices [@B128]. EpiVeta consists of a conjugate of a peptide aptamer for EpCAM and an MPC polymer. The aptamer enables the versatility of the conjugation process, while the zwitterionic membrane‐mimicking polymer MPC consists of methacrylate with a phosphoryl‐choline polar group and is used to reduce the non‐specific binding of proteins to material surfaces [@B128]. In addition, Xu et al. reported a two-stage microfluidic platform termed the ExoPCD chip for EV on-chip isolation and *in situ* electrochemical analysis of exosomes from human serum using DNA aptamer sensors [@B129]. The ExoPCD chip utilized magnetic enrichment based on the specific recognition of the phosphatidylserine-Tim4 protein combined with a novel signal transduction pathway to detect CD63-positive exosomes with high sensitivity using only 30 µL of serum. Samples from liver cancer patients and healthy controls were distinguished by this chip, demonstrating that it is a promising tool for exosome analysis and non-invasive diagnostics [@B129]. Additionally, in developing a diagnostic tool based on the recognition of the surface protein CD63, Wang et al. fabricated a device consisting of three surface- enhanced Raman scattering (SERS) probes coupled with CD63 aptamer-based magnetic substrates for screening and detecting a broad range of exosomes [@B130]. Importantly, to simultaneously detect multiple types of exosomes, the gold nanoparticle probe was modified with different Raman reporters, each with a specific aptamer targeting the exosomes of interest. This system demonstrates great potential for further clinical applications in cancer screening because it can successfully detect target exosomes in blood samples from patients with breast cancer, colorectal cancer or prostate cancer [@B130].

### Challenges to be addressed

Numerous new platforms have been developed to address the technical challenges in conventional methodologies regarding separation/isolation/c apture of exosomes. Researchers at the Chinese Academy of Sciences have developed an aptamer- based fluorescence polarization assay with a one-step mix-and-read platform for exosome quantification that requires less than 1 µL of plasma and has no purification or amplification step [@B131]. This technique, named the AFPExo assay, was developed to overcome the problem of exosome loss during conventional purification/isolation steps, such as ultracentrifugation, ultrafiltration and size exclusion chromatography. This assay is based on the principle that the molecular mass of dye-labeled aptamers is significantly altered after exosome binding, causing a significant change in the fluorescence polarization signal as analyzed with a plate reader. Furthermore, such signals are amplified by the inherent large mass/volume of exosomes. This assay can analyze as many as 5 × 10^5^ exosomes in 1 μL within 30 minutes with a detection limit of 500 exosomes per microliter [@B131].

Furthermore, it is often desirable or necessary to release the captured exosomes from aptamers immobilized on a solid matrix. This can be achieved by the use of chelating agents, such as EDTA, which removes magnesium ions and disrupts the 3D structure of the aptamer, resulting in the release of the bound target. Unfortunately, such a chelating agent-based strategy may not work with all aptamers. Ideally, an affinity-based isolation technique should deliver intact exosomes that retain structural integrity and biological function for further downstream applications. To this end, Zhang and colleagues designed a CD63 aptamer- and magnetic bead-based approach that can be used to rapidly isolate exosomes and subsequently release intact captured exosomes within 90 minutes through the use of a DNA structure-switch aptamer [@B132]. The functional competence of the exosomes released after capture was confirmed with a wound healing assay [@B132].

Aptamer-guided exosome therapeutics
-----------------------------------

While the technologies for aptamer-based exosome diagnostics have been developed extensively, relatively few studies that have evaluated aptamer-targeted exosome delivery systems have been reported. Wan et al. reported aptamer-targeted exosomes carrying paclitaxel, an anticancer drug commonly included in chemotherapy regimens, as a new platform for clinical implementation in cancer treatment [@B133]. In this study, the nucleolin-targeting aptamer AS1411 was covalently conjugated to cholesterol-PEG and subsequently grafted onto mouse dendritic cell membranes. These cells were then mechanically extruded to create aptamer-guided exosomes. With this extrusion-based strategy, approximately 3 × 10^10^ aptamer-guided exosomes with a peak size of 105 nm were obtained from \~1 × 10^7^ cells within one hour. Cholesterol-PEG2000 was chosen because of its amphiphilicity and relative rigidity to stabilize exosomes through hydrophobic- hydrophobic interactions at the lipid bilayer. The strategy for synthesizing the cholesterol-PEG2000- aptamers could potentially be utilized for large-scale production of targeted exosomes secreted from immune cells for the treatment of different cancers. This methodology was proposed to be potentially safer than cell-based immunotherapy (e.g., CAR T-cell therapy) because the cells used to prepare the exosomes can be obtained from the patients who need the therapy. Such patient-derived exosomes can be used for drug loading without the need for genetic engineering [@B133]. In an alternative approach, the orientation of the aptamer ligand on the surface of the exosomes was used to reprogram exosomes to control siRNA/miRNA loading and surface ligand display on exosomes with an RNA aptamer, which resulted in efficient targeted exosome delivery and cancer suppression [@B134]. Specifically, these authors engineered an RNA nanostructure with a three-way junction to control the ligand display on the surface of the EVs. The placement of membrane-anchoring cholesterol at the tail of the three-way arrow resulted in the display of the RNA aptamer or folate on the outer surface of the vesicles. In contrast, the placement of cholesterol at the arrowhead of the three-way arrow resulted in partial loading of RNA nanoparticles into the vesicles. As a result, the RNA nanostructure was directionally linked to the lipid bilayer membrane of the EVs, and the targeting ligands decorated the outer surface of the EVs. Such orientation-engineered ligand-displaying EVs could specifically deliver siRNA to cells and achieve an efficient blockade of tumor growth in the three cancer models studied [@B134]. Most recently, the aptamer sgc8, which can specifically recognizes membrane-bound protein tyrosine kinase 7 (PTK7), was conjugated to a diacyllipid via a PEG linker in a targeted anticancer therapeutic delivery platform [@B135]. The exosomes secreted by immature dendritic cells were loaded with doxorubicin by electroporation, followed by the surface functionalization of vesicles with the targeting ligand via the hydrophobic interaction between the diacyllipid tail of the aptamer conjugates and the phospholipid bilayer of the exosomes [@B135]. Such engineered sgc8-guided exosomes showed selective and dose-dependent cytotoxicity to human leukaemia (CEM) cells. Regarding the cellular uptake mechanism, studies showed that among multiple endocytosis pathways, clathrin-mediated endocytosis played a major role in sgc8 aptamer-mediated cellular internalization. These results indicate that the targeting ligands themselves may affect the interaction of exosomes with cells [@B135]. However, whether other aptamer-target pairs also affect exosome uptake by various types of cancer cells remains to be ascertained. Figure [5](#F5){ref-type="fig"} illustrates a typical therapeutic application of aptamer-guided EVs *in vivo*.

Commentary on aptamer-guided exosome theranostics
-------------------------------------------------

The capture of exosomes using aptamers against exosomal markers such as tetraspanins and other cancer-specific markers, followed by the quantitative assessment of a disease-specific marker, constitutes an invaluable strategy for detecting disease at an early stage, monitoring the treatment response and making accurate prognostic predictions. The fact that there are more circulating exosomes in the peripheral blood of tumor patients than in that of healthy subjects suggests that tumor-derived exosomes are a potentially useful noninvasive diagnostic tool. The commonly used techniques to detect and quantify individual exosomes include nanoparticle tracking analysis (NTA) and flow cytometry. While the results obtained from NTA are subject to interference from contaminating lipoproteins and protein aggregates, which are similar to exosomes in size and density, most flow cytometers are unable to detect vesicles smaller than 100 nm. On the other hand, the specific detection of exosomal surface proteins enables an effective determination of exosomes. However, ELISA requires a relatively large number of exosomes with a detection limit of approximately 10^7^ particles/ μL. Fortunately, fluorescence and electrochemical platforms with specifically designed aptamers can be highly sensitive. Compared with antibodies, aptamers have superior performance because they are much smaller. For instance, an EpCAM aptamer was shown to have better tumor penetration, more homogeneous distribution and better retention *in vivo* than an EpCAM antibody in a mouse xenograft tumor model [@B84]. Indeed, antibodies have poor access to intracellular targets and are more immunogenic and thermally unstable [@B136]. Other limitations of antibodies have been extensively reported, including the high production costs, unexpected pharmacokinetic profiles, unclear modes of action, poor tissue penetration and heterogeneous distribution [@B137], [@B138]. In contrast, aptamers have high affinity for the targeted exosomal membrane proteins [@B139]. Moreover, exosomes have a molecular mass of approximately 3.3 × 10^7^ kDa [@B140], and aptamers are much smaller than antibodies (6\~10 kDa vs. 150 kDa) [@B141]. An IgG molecule occupies an area of \~77 nm^2^, while a 25-nt aptamer covers an area of \~ 10 nm^2^. If both the antibody and 25-nt aptamer were conjugated to a single fluorophore or HRP, then the exosome surface area covered by one antibody would be equal to that of multiple aptamers if all other parameters were similar (e.g., equilibrium dissociation constant, on-rate and off-rate). Therefore, the use of aptamers as binding ligands in lieu of using antibodies will allow the more robust isolation and detection of exosomes. In addition, nucleic acid chemistry enables the large-scale and economical synthesis of aptamers with minimum batch-to-batch variations. Due to these distinct advantages, aptamers are becoming a highly attractive class of targeting ligands for engineering exosomes in theranostic applications (summarized in **Table [2](#T2){ref-type="table"}**).

Prospects for next-generation theranostics
==========================================

Since its humble beginnings 30 years ago, aptamer technology is now paving the way for the flourishing development of new and effective diagnostic and therapeutic tools for major diseases [@B142]-[@B146]. Taking advantage of their small size compared to antibodies and their exquisite binding affinity and specificity [@B112], aptamers can bind to some otherwise inaccessible targets, thereby increasing tissue penetration and conferring enhanced therapeutic efficacy [@B147], [@B148]. Chemical engineering and nanotechnological efforts have led to the generation of chemically modified aptamers with improved pharmacokinetic profiles *in vivo* [@B114]. Moreover, with their advantages of cost-efficiency, time-saving, minimal batch-to-batch variation and with the ability to release intact exosomes after purification, aptamers have become robust tools for both basic research and clinical translation in exosome-based targeted theranostics [@B112], [@B121]. Furthermore, aptamers against disease-specific exosomes can be selected using modified SELEX techniques such as counter-SELEX to enhance the specificity [@B149], thereby empowering targeted exosome therapeutics. At the diagnostic front, a number of advanced diagnostic tools for exosome isolation and/or detection have emerged to provide unprecedented sensitivity and specificity, such as nPLEX [@B13], the fluorescence-based microfluidic chips [@B150], the alternating current electrokinetic microarray chip [@B151], and interferometric imaging [@B152]. Future work will focus on expanding the development of assays for accurate, reproducible, sensitive, and rapid EV detection without a requirement for separation and washing steps. Eventually, clinically validated assays must be adapted for direct implementation in modern automated pathology laboratories. Ideally, some of these next-generation diagnostics will be adapted as hand-held devices for point-of-care use.

A key challenge in exosome research and development is exosome heterogeneity because each exosome is unique in its molecular and biochemical composition [@B153]. Currently, there is an acute lack of robust methods for isolating or purifying exosomes and microvesicles for both diagnostic and therapeutic applications. Although most published work in the field of EV research has focused on exosomes, hence the exosome-centric coverage in this review, microvesicles have emerged as key players in mediating intercellular communication between cancerous and stromal cells and in orchestrating complex pathophysiological processes [@B154]-[@B159]. Therefore, the next decade will witness renewed efforts in the development of microvesicle-based theranostics. Indeed, recent seminal work by Coffey and colleagues, for the first time, has established CD81/CD9/CD63 and annexin A1 as specific biomarkers for exosomes and microvesicles, respectively [@B7]. The future development of aptamers against these newly identified EV markers will greatly enhance our ability to effectively and efficiently isolate EV subpopulations. We will then be able to elucidate the mechanisms underlying EV biogenesis and heterogeneity and translate the results of EV research to pathology laboratories and the clinic.
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![Extracellular vesicles as diagnostic markers and next-generation therapeutics. Exosomes sized 50 to 150 nm are released from most cell types upon fusion of an intermediate endocytic compartment, the multivesicular body, with the plasma membrane. Microvesicles are released by direct budding from the cell surface. Both types of vesicles are composed of an aqueous core and a lipid bilayer membrane and contain a variety of proteins, DNAs, RNAs, lipids and other metabolites. Image of the circulatory system was modified from <https://commons.wikimedia.org/wiki/File:Circulatory_System_en.svg> by LadyofHats, with permission.](thnov10p3849g001){#F1}

![Comparison of ExoScreen and the conventional method of biomarker detection. ExoScreen can be performed without a prior purification step. This system uses photosensitizer beads composed of streptavidin-coated donor beads to capture biotinylated antibodies in the analyte, and these beads are excited with a laser at 680 nm. Singlet oxygen is released and excites the acceptor beads, which are conjugated to a second antibody recognizing an epitope in the analyte, to amplify the fluorescence signal. This system emits light at 615 nm only when (i) exosomes are captured by both antibodies (CD147 and CD9) and (ii) the exosomes are smaller than 200 nm. Images of the plate reader and immunoblotting technique were modified from <https://www.perkinelmer.com/category/microplate-readers>, and <https://www.bioradiations.com/the-how-and-why-of-normalizing-your-western-blots/>, respectively, with permissions.](thnov10p3849g002){#F2}

![Major steps involved in one cycle of cell-SELEX to isolate aptamer probes for cell tracking. Briefly, after the incubation of a random single-stranded aptamer library with target cells and subsequent washing steps, negative selection is performed to remove nonspecific binding sequences. Subsequently, the target-bound sequences are PCR-amplified prior to being subjected to the next cycle. The aptamers can then be attached to therapeutic cells *ex vivo* to track their biodistribution or differentiation in stem cell therapy following implantation into the host. Alternatively, the labeled aptamers can be used for specifically monitoring target cells. Images of the bone marrow and mice were modified from <https://commons.wikimedia.org/wiki/File:Gray72.png> by Henry Vandyke Carter and from <https://www.stockvault.net/photo/126860/white-mouse> by 2happy, respectively, with permissions.](thnov10p3849g003){#F3}

![A scheme of exosome isolation and/or analysis via an electrochemical aptasensor. In this platform, the electrode is made of gold and carbon surfaces for the detection of different target analytes, e.g., tumor-derived exosomes of various sizes. Changes in the redox signal are proportional to the concentration of exosomes. After aptamer immobilization followed by incubation with exosomes, the signal is typically significantly suppressed due to the decreased electrode surface area. The image of the potentiostat was modified from <https://mep.metrohm.com.au/2017/07/29/metrohm-autolab-portable-potentiostat-kit/> with permission.](thnov10p3849g004){#F4}

![A typical manufacturing cycle of the EV-based engineering of exosomes or microvesicles for targeted therapeutics. In allogeneic EV therapy, EV-producing cells are isolated from individuals who are not genetically identical and then manipulated *in vitro* to load the therapeutic cargo. Subsequently, aptamers are decorated on the exosome or microvesicle surface to generate aptamer-targeted exosomes or microvesicles that are ready to deliver therapeutic cargos in a targeted system. In autologous EV therapy, the EV-producing cells are obtained from the patient requiring treatment, as EVs can be readily isolated from body fluids or produced by cultured mesenchymal stem cells from the patient, and then transferred back to the same patient after *in vitro* cargo loading and surface functionalization with aptamers. Images of the silhouette (mouse and girl) were downloaded for free from <https://www.nicepng.com/ourpic/u2q8y3a9a9i1a9y3_mouse-silhouette-sidewasy-mouse-clip-art-silhouette-mouse/>, and <https://www.freepik.com/free-vector/black-girl-silhouettes_764970.htm#page=1&query=girl%20silhouette&position=1>, designed by Freepik.](thnov10p3849g005){#F5}

###### 

Typical and most recent techniques of EV-based liquid biopsy with potential applications to cancer diagnosis.

  Technique                                                                             Biomarker                                                                                                                            Cancer                          Volume of samples     Time         Limit of detection                                                                     Reference
  ------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------ ------------------------------- --------------------- ------------ -------------------------------------------------------------------------------------- ----------------
  ExoDx^TM^ Prostate (The first exosome-based liquid biopsy test approved by the FDA)   ERG, PCA3, and SPDEF (internal reference)                                                                                            Prostate                        \~ 20 mL (urine)      NA           prostate-specific antigen 2-10 ng mL^-1^; SPDEF detected at \>30 copies per reaction   [@B61], [@B77]
  ExoDx^TM^ Lung (ALK)                                                                  EML4-ALK                                                                                                                             Lung                            0.9-1.5 mL (plasma)   NA           2.5 copies per reaction                                                                [@B78], [@B79]
  ExoTEST                                                                               CD63, Rab5b, and caveolin-1                                                                                                          Melanoma                        100 µL (plasma)       \~ 3 days    less than 50 pg of targeted exosomal protein                                           [@B39]
  ExoScreen                                                                             CD9, CD63, CD147, CEA, and CA19-9                                                                                                    Colorectal                      5 µL (serum)          \~ 120 min   NA                                                                                     [@B63]
  Nanoplasmonic assay (nPLEX)                                                           CD24, CD41, CD45, CD63, CA125, CA19-9, D2-40, EpCAM, EGFR, HER2, CLDN3, and MUC18                                                    Ovarian                         NA (ascites)          \~ 30 min    \~ 3000 exosomes                                                                       [@B13]
  EV array                                                                              \~ 60 biomarkers, including tetraspanin markers, EpCAM, NY-ESO-1, MUC16, CEA, CD151, CD142, CD146, EGFR, PDL-1, MET, and p53, CD13   Non-small cell lung carcinoma   1-10 µL (plasma)      \~ 3 days    2.5 × 10^4^ per microarray spot (\~1 nL)                                               [@B66]
  Microfluidic chip (self-assembled 3D herringbone nanoporous structure)                CD24, EpCAM, and folate receptor alpha proteins                                                                                      Ovarian                         2 µL (plasma)         \~ 90 min    10 exosomes μL^-1^                                                                     [@B67]
  Nickel-based isolation (NBI)-alpha or digital PCR                                     PSMA, KRAS, and BRAF                                                                                                                 Prostate, colorectal            20 µL (plasma)        \~180 min    NA                                                                                     [@B68]
  ExoProfile chip (3D porous serpentine nanostructures)                                 EGFR, HER2, CA125, FRα, CD24, EpCAM, CD9, and CD63                                                                                   Ovarian                         10 µL (plasma)        \~180 min    21 exosomes μL^-1^                                                                     [@B69]
  Surface acoustic wave (SAW)-based microfluidic chip                                   miR-21, miR-550, and miR-146a                                                                                                        Liver, pancreatic, oral         20 µL (plasma)        \~ 30 min    1 pM (miRNA concentration)                                                             [@B70]
  Antibody-coated magnetic microbeads followed by flow cytometry                        CD63, CD81, CD9, and EpCAM                                                                                                           Prostate                        500 µL (urine)        \~ 2 days    30 ng of exosomes (1.37 × 10^7^ particles)                                             [@B75]
  Droplet digital PCR                                                                   miR-29a                                                                                                                              Healthy volunteers              0.3-2 µL (urine)      NA           5 copies μL^-1^                                                                        [@B76]

###### 

Summary of aptamers used in aptamer-guided exosome theranostics.

                      Aptamer                                                          Cells producing exosomes (protein target)                                                                   Clinical samples/ potential applications                   Reference
  ------------------- ---------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------- ---------------------------------------------------------- -----------
  **Diagnostics**     A8                                                               HCT116, SW480, PC3, HeLa (HSP70)                                                                            Urine from patients with breast, lung, or ovarian cancer   [@B121]
  MO-1, MO-2          293T, HeLa S3 (tetraspanin)                                      Cervical cancer                                                                                             [@B122]                                                    
  H2 and SYL3C        BT-474 and SK-BR-3 (HER2 and EpCAM)                              Breast cancer                                                                                               [@B123]                                                    
  LZH8                HepG2                                                            Hepatocarcinoma                                                                                             [@B125]                                                    
  MUC_3               SGC7901 (Mucin 1)                                                Plasma from gastric cancer patients                                                                         [@B126]                                                    
  EpCAM/ Ep114        HT-29, HCT-15, and MCF-7 (EpCAM)                                 Colorectal, and breast cancer                                                                               [@B127], [@B128]                                           
  CD63                HepG2, A549, and MCF-7                                           Serum from patients with gastric cancer, plasma from patients with non-small lung cancer or breast cancer   [@B127], [@B129], [@B131], [@B132]                         
  H2, CEA, and PSMA   SKBR3 (HER2), T84 (carcinoembryonic antigen), and LNCaP (PSMA)   Blood from patients with breast cancer, colorectal cancer, or prostate cancer                               [@B130]                                                    
  **Therapeutics**    AS1411                                                           Dendritic cells (nucleolin)                                                                                 Breast cancer                                              [@B133]
  PSMA and EGFR       HEK293T                                                          Breast, prostate, and colorectal cancer                                                                     [@B134]                                                    
  sgc8                Dendritic cells (PTK7)                                           Leukemia/ Lymphoma                                                                                          [@B135]                                                    
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